Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's original application for dapagliflozin tablets (generic), enabling market entry for the SGLT2 inhibitor.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s generic dapagliflozin (ANDA 211535) as an original application. The approval makes a generic version of dapagl…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Ascend Laboratories, LLC)
FDA approved the original generic application for dapagliflozin, enabling a generic version of the SGLT2 inhibitor used for type 2 diabetes …
-
FDA approval · 2026-04-06FDA Tentative Approval: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA issued tentative approval for Sun Pharmaceutical's generic dapagliflozin and metformin hydrochloride tablet (ANDA 211491), enabling pote…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus [EARLY_Phase 1]
A single-center, open-label Phase 1 study evaluating the safety and tolerability of Exenatide circular RNA-Lipid Nanoparticle Injection (CR0…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-06FDA Tentative Approval: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA issued tentative approval for Lupin's generic combination of dapagliflozin and metformin hydrochloride, enabling potential U.S. marketin…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes [Phase 4]
A Phase 4 clinical trial evaluating how weekly insulin icodec compares with daily basal insulins in adults with Type 2 diabetes is currently…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH [Phase 4]
A Phase 4 clinical trial at Massachusetts General Hospital is studying genetic links related to exposure to oral semaglutide, with participa…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND SAXAGLIPTIN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for a generic fixed-dose combination of dapagliflozin and saxagliptin, manufactured by Novadoz Pharmac…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Ajanta Pharma USA Inc.)
FDA approved the original application for dapagliflozin generic from Ajanta Pharma USA Inc., making the SGLT2 inhibitor available as a gener…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application (ANDA) for Dapagliflozin and Metformin Hydrochloride from Aurobindo Pharma Limited, a generic combinat…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes [Phase 3]
Phase 3 study evaluating a triple-combination regimen of Prusogliptin, Dapagliflozin, and extended-release Metformin for type 2 diabetes; th…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan [EARLY_Phase 1]
This early-phase trial plan explores the cardiovascular benefits of SGLT2 inhibitors and ketone strategies in people with type 2 diabetes an…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Autologous Islet Transplantation for Diabetes [EARLY_Phase 1]
An early-phase trial (Phase 1) is enrolling by invitation for autologous islet transplantation as a treatment for Type 2 diabetes at Shangha…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Sandoz Inc)
FDA approves Sandoz's generic dapagliflozin under Original Application. The approval makes a generic version available for the same indicati…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets [Phase 1]
Phase 1 clinical trial update evaluating the effects of food on pharmacokinetics and the safety of multi-dose chiglitazar/metformin extended…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals [NA]
This clinical trial assesses whether whey protein ingestion improves glucose control in people with prediabetes or type 2 diabetes, and is c…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study [NA]
This clinical trial assesses the effects of vasopressors ephedrine, phenylephrine, and norepinephrine on myometrial contractility in pregnan…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes
A clinical trial is recruiting to assess pancreatic dysfunction in patients with Type 2 diabetes, investigating pancreatogenic diabetes mell…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older [NA]
The PIVOT trial evaluating EHR-integrated lifestyle interventions for adults aged 50 and older is currently active but not recruiting.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved the Original Application (ANDA) for dapagliflozin from Florida Pharmaceutical Products, LLC.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' original application for a generic fixed-dose combination tablet of dapagliflozin and metformin hydroc…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original ANDA for dapagliflozin tablets, a generic SGLT2 inhibitor used to improve glycemic control …
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approves the generic dapagliflozin from Macleods Pharmaceuticals Limited under an Original Abbreviated New Drug Application (ANDA).
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for dapagliflozin from Zydus Lifesciences Limited, making a generic SGLT2 inhibitor available for glyc…